Austin-based Genprex, Inc., a clinical-stage gene therapy company specializing in cancer and diabetes treatments, is making strides with its lead product candidate REQORSA (GPX-001). REQORSA has shown great promise in treating non-small cell lung cancer and small cell lung cancer. In addition, the company is in the process of developing GPX-002, a gene therapy still in a preclinical stage, as a potential treatment for diabetes. Founded in 2009, Genprex, Inc. has continued to prioritize innovation and cutting-edge research in its mission to improve treatment outcomes for cancer and diabetes patients.